0001179110-20-002963.txt : 20200303
0001179110-20-002963.hdr.sgml : 20200303
20200303191100
ACCESSION NUMBER: 0001179110-20-002963
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200301
FILED AS OF DATE: 20200303
DATE AS OF CHANGE: 20200303
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Albers Jeffrey W.
CENTRAL INDEX KEY: 0001638474
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37359
FILM NUMBER: 20684938
MAIL ADDRESS:
STREET 1: BLUEPRINT MEDICINES CORP.
STREET 2: 215 FIRST STREET, SUITE 340/350
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Blueprint Medicines Corp
CENTRAL INDEX KEY: 0001597264
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 45 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-374-7580
MAIL ADDRESS:
STREET 1: 45 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
edgar.xml
FORM 4 -
X0306
4
2020-03-01
0
0001597264
Blueprint Medicines Corp
BPMC
0001638474
Albers Jeffrey W.
C/O BLUEPRINT MEDICINES CORPORATION
45 SIDNEY STREET
CAMBRIDGE
MA
02139
1
1
0
0
CEO and President
Common Stock
2020-03-01
4
A
0
45000
0
A
123711
D
Stock Option (Right to Buy)
54.13
2020-03-01
4
A
0
90000
0
A
2030-03-01
Common Stock
90000
90000
D
The reported transaction involved the Reporting Person's receipt of a grant of 45,000 restricted stock units under Issuer's 2015 Stock Option and Incentive Plan. The Reporting Person has reported prior awards of restricted stock units in Table II of Form 4. The total reported in Column 5 includes the 45,000 newly awarded restricted stock units, 29,750 previously reported restricted stock units, 7,438 of which vested on March 1, 2020, and 48,961 shares of common stock.
This option vests with respect to 1/48th of the shares underlying the option on April 1, 2020 and as to an additional 1/48th of the shares underlying the option each month thereafter.
/s/ Christopher Frankenfield, Attorney-in-Fact
2020-03-03